da-kuk/E+ via Getty Images
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) recently got approved for Pyrukynd (mitapivat) in Pyruvate Kinase - PK - deficiency. However, the stock has lagged. While that is par for the course for biotech stocks to have strong post-climax depressions, a 35% fall in 3 months after approval sounds
About the TPT service
Thanks for reading. At the Total Pharma Tracker, we offer the following:-
Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.
For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.
Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you.
